Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Increase in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 121,000 shares, an increase of 103.0% from the December 15th total of 59,600 shares. Based on an average trading volume of 153,600 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.5% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Trading Down 0.6 %

NASDAQ:BOLT traded down $0.00 on Tuesday, reaching $0.53. The company’s stock had a trading volume of 7,945 shares, compared to its average volume of 145,766. Bolt Biotherapeutics has a 12-month low of $0.48 and a 12-month high of $1.56. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market cap of $20.13 million, a price-to-earnings ratio of -0.31 and a beta of 0.96. The stock has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.64.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.02 million. On average, equities analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. FMR LLC raised its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 115,386 shares of the company’s stock after purchasing an additional 28,773 shares during the quarter. FMR LLC owned 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. 86.70% of the stock is owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.